Podcasts about eligible

Last Tuesday, MLB Commissioner Rob Manfred dropped a bomb on the baseball community with his announcement that the lifetime bans of 17 individuals were lifted, effective immediately. With the ban lifted, all 17 are now eligible for the Baseball Hall of Fame, but let's be real; Pete Rose and 16 others are now eligible for Cooperstown. Jim covers what happened and walks through the list of all of the individuals impacted. Then, he takes a quick look into the Hall of Fame cases of Shoeless Joe Jackson, Eddie Cicotte, Benny Kauff, and Rose (17:35). Finally, he reviews what the 2028 Classic Baseball Era ballot could look like, which is the first ballot any of these players could potentially land on (36:47).

Learn more about your ad choices. Visit podcastchoices.com/adchoices

See omnystudio.com/listener for privacy information.

Case gives his take on Pete Rose and Shoeless Joe Jackson becoming Hall of Fame eligible. Plus, Sean goes deep inside the mental makeup you need at the plate that he thinks has helped the likes of Trent Grishom of the Yanks to turn into a weapon at the dish. Full Youtube Broadcast Here: https://youtu.be/EMlbfmIt2ZM BetOnline is The World's Most Trusted Betting Platform and your #1 source for all your sports betting action! Baseball season is in full swing, and we're into the home stretch for NBA and NHL Playoffs has more ways to stay in on the action with the latest odds, news and scores, even LIVE in-game betting while the games are being played. With the largest selection of odds on everything from the MLB, NHL and UFC, BetOnline remains the #1 online source for all your sports wagering info. In between games head over to the BetOnline Casino with all the top Vegas style Games, including Poker and Live Casino! BetOnline - The Game Starts Here!

Big O talks Pete Rose 051425

The Menendez brothers, Lyle and Erik, who were convicted for murdering their parents in 1989, are now eligible for parole after their sentences were reduced from life in prison to 50 years to life, according to AP. KSL Legal Analyst Greg Skordas discusses the opportunity the brothers have for parole and how the sentencing has shifted and what factors played into that.  

A daily non-partisan, conversational breakdown of today's top news and breaking news stories Headlines: – Welcome To Mo News  (02:00) – ​​Trump In The Gulf: Says U.S. Will Remove All Sanctions On Syria (06:20) – Biden Aides Discussed Wheelchair Use If He Were Re-Elected, New Book Says (19:30) – United Air Warns Flyers of Reduced Newark Service Through Summer (27:40) – Annual Inflation Rate Hit 2.3% in April, Less Than Expected And Lowest Since 2021 (30:30) – Menendez Brothers Now Eligible For Parole (32:50) – AMC to Slash Movie Ticket Prices by 50% on Wednesdays (36:30) – Mosheh at The Sweet & Snacks Expo In Indianapolis (38:20) – On This Day In History (44:10) Thanks To Our Sponsors: – LMNT - Free Sample Pack with any LMNT drink mix purchase – Shopify – $1 per-month trial Code: monews – Sonic Power - 20% off | Promo Code: MONEWS – Surfshark - 4 additional months of Surfshark VPN | Code: MONEWS – Industrious - Coworking office. 30% off day pass – Athletic Greens – AG1 Powder + 1 year of free Vitamin D & 5 free travel packs

See omnystudio.com/listener for privacy information.

News Whip: Air BNB offering new features. San Clemente looking for “just right” sand. IN-N-OUT to eliminate bad dyes in their food. // Disneyland makes some changes to “It's a Small World”. Breaking news: Menendez Brothers resentenced 50 years to life, eligible for parole. #Menene // BREAKING: Menendez brothers resentencing; 50 years to life, eligible for parole // Adam Carolla's connection to Menendez brother's lawyer Mark Geragos. Carolla was the impetus for Geragos taking the Menendez case. #MarkGeragos #MenendezFree The Stand-Up Comedy Club of Bellflower 2nd show tickets available  Saturday, May 24th –10pm show. #AdamCarolla #standup #Comedy   

See omnystudio.com/listener for privacy information.

John Shea joins Silver & JD to react to Pete Rose becoming Hall of Fame eligible and what it means for other great like Barry Bonds who are left out of CooperstownSee omnystudio.com/listener for privacy information.

Papa & Silver Hour 1: Warriors Season on the Brink, Pete Rose Hall of Fame Eligible, & John SheaSee omnystudio.com/listener for privacy information.

Mike Mulligan and David Haugh reacted to the late Pete Rose being reinstated by MLB, making him eligible for the Hall of Fame.

In the second hour, Mike Mulligan and David Haugh debated if a pair of previously banned players in the late Pete Rose and "Shoeless" Joe Jackson deserve to be inducted into the Hall of Fame after baseball reinstated them Tuesday. After that, Score baseball insider Bruce Levine joined the show to discuss the Cubs' walk-off 5-4 win against the Marlins on Tuesday at Wrigley Field.

Nearly 36 years after Erik and Lyle Menendez took their parents' lives with shotguns in a crime that captivated the nation, the brothers appeared via video before a Los Angeles judge who would determine their potential release from prison.See omnystudio.com/listener for privacy information.

After MLB commissioner Rob Manfred lifted Pete Rose's lifetime ban, do you think he will be elected to the Hall Of Fame?

Pete Rose now eligible for the MLB H.O.F full 583 Wed, 14 May 2025 15:51:04 +0000 DrA8fCgSmHg7pWd3VpI4GkCkjJ9M6iIs mlb,reds,society & culture Cody & Gold mlb,reds,society & culture Pete Rose now eligible for the MLB H.O.F Hosts Cody Tapp & Alex Gold team up for 610 Sports Radio's newest mid-day show "Cody & Gold."  Two born & raised Kansas Citians, Cody & Gold have been through all the highs and lows as a KC sports fan and they know the passion Kansas City has for their sports teams."Cody & Gold" will be a show focused on smart, sports conversation with the best voices from KC and around the country. It will also feature our listeners with your calls, texts & tweets as we want you to be a part of the show, not just a listener.  Cody & Gold, weekdays 10a-2p on 610 Sports Radio.  2024 © 2021 Audacy, Inc. Society & Culture False https://player.amperwavepodcasting.com?feed-link=htt

(00:00-11:49) – MLB announce Pete Rose is eligible for the Hall of Fame. (11:49-21:32) – What did Tim Kurkjian have to say about Pete Rose being eligible for the Hall of Fame? (21:32-31:04) – Is Pete Rose deserving of the Hall of Fame? (31:04-39:28) – Peacock exclusive games.

In this EPISODE I'm sharing on: How my clients meet godly single eligible men Changes my clients make for dating to become simple for them To work with me 1-1 to go from single to married in a year Click the link below

Papa & Silver Hour 1: Warriors Season on the Brink, Pete Rose Hall of Fame Eligible, & John SheaSee omnystudio.com/listener for privacy information.

John Shea joins Silver & JD to react to Pete Rose becoming Hall of Fame eligible and what it means for other great like Barry Bonds who are left out of CooperstownSee omnystudio.com/listener for privacy information.

Pete Rose is finally eligible for the Hall, Michelangelo, and Air Force One is up for debate "This Evening"

In sports with Ted Woodward, we hear about baseball reversing course on what a lifetime ban actually means.

After previously being on the ineligible list, Pete Rose and Shoeless Joe Jackson are now eligible to be inducted into Baseball’s Hall of Fame. The two immensely talented players were both tainted by scandal. Rose admitted to betting on games while Jackson and seven other teammates were banned for allegedly fixing the World Series in 1919. Geoff Bennett discussed more with Howard Bryant of ESPN. PBS News is supported by - https://www.pbs.org/newshour/about/funders

BREAKING Pete Rose and Shoeless Joe Eligible for HOF, Tatum's Injury, and Visiting Australia - T H2

Hour 2 – The Drive reacted to the breaking news that the commissioner of baseball has made Peter Rose and Shoeless Joe Jackson Hall of Fame eligible.

(0:00) Mazz opens The Baseball Hour discussing the Red Sox 14-2 loss to the Detroit Tigers on Monday night. (13:55) Dan Shaughnessy joins Mazz on The Baseball Hour to discuss Pete Rose and the Hall of Fame. (28:39) Trivia Tuesday! Plus, final thoughts from the callers!

Two of baseball's most controversial figures have been posthumously reinstated. Correspondent Gethin Coolbaugh reports.

In this EPISODE I'm sharing on: What it looks like to date single eligible men You'll learn what it looks like to date men you're excited about I'm sharing what you've been doing wrong And what needs to change To work with me 1-1 to go from single to married in a year Click the link below

Customers again will be returned to Central Hudson Philipstown residents and businesses receiving fixed-rate electricity through Hudson Valley Community Power will be transferred back to Central Hudson because the program administrator ran out of time to extend the contract. In what is known as a community choice aggregation (CCA) program, municipalities contract with a third-party supplier to offer residents and businesses a fixed rate for electricity, although Central Hudson continues to provide delivery and billing. Cold Spring, Nelsonville, Philipstown and nine other municipalities (not including Beacon) agreed to participate. Residents and businesses are added to the program automatically but can opt out. Hudson Valley Community Power was negotiating to extend a contract that ends June 30. Mike Gordon, founder and chief strategy officer for the program administrator, Joule Assets, said in a letter to municipalities that "times are deeply uncertain at the moment and electricity prices rose quickly in response." Nelsonville Mayor Chris Winward read the letter at the April 21 Village Board meeting. Although prices have fallen more recently, Gordon said Joule lacked enough time to meet new guidelines created by the state utility regulator, the Public Service Commission, to notify and educate customers about new pricing before June 30. Because the "political and economic environment is so volatile," Joule does expect "opportunities to lock in some advantageous pricing" over the next two to three months. Joule will spend those months learning "how best to work through" the new PSC regulations, said Jessica Stromback, the company's CEO. "The order is, let everybody go back to the utility and not scramble," she said on Wednesday (May 7). "That process is smooth; the utility understands it. There's no interruption in service." Under the current contract, residents and businesses in the CCA pay a default rate of 12.24 cents per kilowatt hour for 100 percent renewable energy in Cold Spring and 11.24 cents per kilowatt-hour for 50 percent renewable energy in Nelsonville and Philipstown. Those customers will be charged Central Hudson's variable rate starting July 1. As of April 10, Central Hudson's standard supply rate was 10.3 cents per kilowatt-hour. Last year's summer rates, when electricity demand is higher, averaged 9.6 cents per kilowatt-hour. (Central Hudson charges a separate rate for delivery.) "[The CCA] pricing was high, but it was locked in and we knew what it would be," Winward said at last month's meeting. "We don't know what the volatility of Central Hudson's rates are going to bring us." The July 1 transition will mark the second time residents and businesses enrolled in Hudson Valley Community Power have been sent back to Central Hudson. A former supplier, Columbia Utilities, defaulted on a contract to provide renewable energy at 6.6 cents per kilowatt-hour for residences and 7.1 cents for small businesses, including those in Beacon, Cold Spring and Philipstown. In April 2022, Columbia notified the PSC that it intended to return customers to Central Hudson. A state judge on Dec. 5 approved a $1.5 million settlement in a lawsuit filed by the municipalities against Columbia Utilities. The company admitted no wrongdoing but agreed to a $1 million payment into a settlement fund and $50,000 monthly payments by June 1, 2025, to cover the balance. The Ulster County judge overseeing the case also approved $286,585 in attorney fees and up to $56,500 in administrative costs. Eligible customers began receiving checks for about $50 last month.

Now with JR actually asking the questions!

We (Paul) missed a few Patreon questions, and so here they are, with answers.

The Packers are done drafting, and Paul, JR, and Matt are here to take you through it! They take on draft weekend itself, the Barryn Sorrell moment and whether he moves the needle at edge, the new focus on beef at offensive line, and whether Matthew Golden and Savion Williams see serious time early. They also discuss how the rest of the division fared, and of course, listener questions!

The Packers are done drafting, and Paul, JR, and Matt are here to take you through it! They take on draft weekend itself, the Barryn Sorrell moment and whether he moves the needle at edge, the new focus on beef at offensive line, and whether Matthew Golden and Savion Williams see serious time early. They also discuss how the rest of the division fared, and of course, listener questions! Hosted on Acast. See acast.com/privacy for more information.

The fixed version, with JR intact, but Paul sounding weird. Hosted on Acast. See acast.com/privacy for more information.

We (Paul) missed a few Patreon questions, and so here they are, with answers. Hosted on Acast. See acast.com/privacy for more information.

In this JCO Article Insights episode, host Jospeh Mathew summaries Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial, by Palmer, et al published December 5, 2024. Transcript Joseph Matthew: Hello and welcome to the Journal of Clinical Oncology Article Insights. I'm your host, Joseph Matthew, and today we will be discussing the article "Long-Term Survival in Resected Pancreatic Ductal Adenocarcinoma with Adjuvant Gemcitabine plus Capecitabine Compared to Modified FOLFIRINOX from the ESPAC-4 and the PRODIGE 24 Trials" by Dr. Palmer et al. To summarize the relevant evidence, the ESPAC-4 was a European phase 3 multicenter randomized clinical trial published in 2017 comparing adjuvant gemcitabine and capecitabine (GemCap) with gemcitabine monotherapy following macroscopic margin-negative resections for operable pancreatic ductal adenocarcinoma (PDAC). The trial had included non-metastatic patients aged 18 years or older, World Health Organization (WHO) performance scores of 2 or less, creatinine clearance of at least 50 mL/min, and a life expectancy of over three months who had not received any prior anticancer treatment. Patients who had undergone R2 resections were selectively excluded. Eligible participants were randomized 1:1 within 12 weeks of pancreatectomy to one of the two treatment arms, with chemotherapy initiated within two weeks from the date of randomization. The regimens involved six cycles, each lasting four weeks, for an overall duration of 24 weeks. In the monotherapy arm, gemcitabine dosed at 1 g/m² was given as an intravenous infusion once a week for three weeks, followed by one week off. In the GemCap arm, capecitabine dosed at 1660 mg/m² was added to gemcitabine, given daily for three weeks, followed by one week off. Patients were followed up every three months, with the primary endpoint being overall survival (OS). The study showed that at a median follow-up of 43.2 months, GemCap was associated with a significantly longer OS than gemcitabine alone. Subsequently, in 2018, the Phase 3 randomized PRODIGE 24 trial was conducted in centers across France and Canada, comparing adjuvant modified FOLFIRINOX (mFOLFIRINOX) with gemcitabine in a similar subset of patients with resected PDAC and reported longer OS with the mFOLFIRINOX regimen. This study, however, had more restrictive eligibility criteria when compared to ESPAC-4, including patients aged under 80 years, WHO performance status of 0 or 1, with no significant cardiovascular disease, and a postoperative serum CA 19-9 of less than 180 U/mL. There was hence a subset of ESPAC-4 patients who did not meet the eligibility criteria for mFOLFIRINOX as set by the PRODIGE 24. The present study was conducted to estimate the overall 5-year survival rates for patients of ESPAC-4 receiving GemCap and gemcitabine, further stratifying survival in either arm according to the status of the surgical margins (R status) and the resected nodes (N status), and also to investigate whether GemCap retained a survival benefit over gemcitabine in PRODIGE 24-ineligible patients. A total of 732 patients, evenly distributed between both arms, were followed up for a median period of 104 months. Adjuvant GemCap was found to retain its survival advantage over gemcitabine, with a significantly longer median OS of 31.6 months when compared to 28.4 months with gemcitabine alone. Further subgroup analysis was performed with reference to the resection margins and the nodal status. As a reminder, in the ESPAC-4 trial, 60% of patients were found to have microscopically positive margins (an R1 resection), and 80% were node-positive. The difference in survival was greater in patients undergoing microscopic margin-negative resections (R0) who experienced a median OS of 49.9 months with GemCap when compared to 32.2 months with gemcitabine. Node-negative patients also had a significantly greater 5-year OS rate with GemCap of 59% versus 53% with gemcitabine monotherapy. However, it is important to note that no significant difference in survival outcomes was observed in margin-positive (R1) or node-positive patients in the two arms. The investigators also evaluated GemCap in the subgroup of 193 patients (comprising 26.4% of the ESPAC-4 cohort) who were not considered to have met the eligibility criteria for PRODIGE 24. The survival benefit of combination therapy was retained in this group, with patients receiving GemCap experiencing a median survival of 25.9 months compared to 20.7 months with adjuvant gemcitabine. Although cross-trial comparisons have limited validity, good agreement was noted in adverse grade 3 or greater toxicity associated with the control gemcitabine arms of ESPAC-4 and PRODIGE 24, serving as the basis for a qualitative comparison of toxicities between mFOLFIRINOX and GemCap. Neutropenia was more prevalent in the GemCap arm, affecting 40.8% of patients compared to 28.4% with mFOLFIRINOX. However, granulocyte colony-stimulating factor (G-CSF) was administered to 62.2% of patients in PRODIGE 24. Palmar-plantar erythrodysesthesia (PPE) was also more prevalent with GemCap. Patients on mFOLFIRINOX were more likely to observe grade 3 or greater fatigue, diarrhea, nausea and vomiting, sensory peripheral neuropathy, and paresthesias. The investigators concluded that GemCap was the standard adjuvant treatment for patients with PDAC undergoing an upfront resection who were not feasible for mFOLFIRINOX. Further exploratory analysis revealed that patients under the age of 70 who had undergone a microscopic margin-negative (R0) resection for node-negative PDAC were likely to derive an OS benefit from the addition of capecitabine to gemcitabine in the adjuvant setting. In contrast, mFOLFIRINOX would be more effective than gemcitabine in patients with positive margins (R1) or involved nodes, as per the PRODIGE 24 trial. Thank you for listening to JCO Article Insights. Please come back for more interviews and article summaries, and be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit ASCO.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

That's a wrap on the 2025 draft, as Tex and Paul take you through an absolutely brilliant experience, filled with great moments. They recap the Packers' day three picks, including a few steals at edge rusher, before tackling some of the interesting UDFAs, including a 220 pound boundary corner. The Packers attacked their positions of need in their typically high-RAS fashion, and it's hard not to be excited about the future.The draft in tiny Green Bay was a huge success, and really couldn't have gone much better. What an absolute blast.

That's a wrap on the 2025 draft, as Tex and Paul take you through an absolutely brilliant experience, filled with great moments. They recap the Packers' day three picks, including a few steals at edge rusher, before tackling some of the interesting UDFAs, including a 220 pound boundary corner. The Packers attacked their positions of need in their typically high-RAS fashion, and it's hard not to be excited about the future.The draft in tiny Green Bay was a huge success, and really couldn't have gone much better. What an absolute blast. Hosted on Acast. See acast.com/privacy for more information.

Paul and Tex recap the first three rounds of the NFL draft from on site, where they hung out in the Titletown district, in Lambeau, by the big stage, and just soaked it all in. We also met a bunch of you, and you're all cool.The guys also discuss Matthew Golden, Anthony Belton, Savion Williams, the best guys remaining, and the Shadeur Sanders situation.

Paul and Tex recap the first three rounds of the NFL draft from on site, where they hung out in the Titletown district, in Lambeau, by the big stage, and just soaked it all in. We also met a bunch of you, and you're all cool.The guys also discuss Matthew Golden, Anthony Belton, Savion Williams, the best guys remaining, and the Shadeur Sanders situation. Hosted on Acast. See acast.com/privacy for more information.

But he's only emotionally available for trolling politicians.

On this pre-draft episode of RAE, Paul, Tyler, and JR discuss who they like, who is likely, the numbers versus the tape, the difficulties in trading down in a bad draft class, the ideal spot to be, Why Packer defenders from Georgia fail, whether they might do that again, a cooperative mock draft, and of course, listener questions!

On this pre-draft episode of RAE, Paul, Tyler, and JR discuss who they like, who is likely, the numbers versus the tape, the difficulties in trading down in a bad draft class, the ideal spot to be, Why Packer defenders from Georgia fail, whether they might do that again, a cooperative mock draft, and of course, listener questions! Hosted on Acast. See acast.com/privacy for more information.

Artie Intel and Micheline Learning report on Artificial Intelligence for The AI Report. Synthesia’s video-generation platform now turns text, PDFs, or URLs into videos in minutes. Gemma 3 dominates as the most powerful open-source model for single-GPU devices. Early tests show it outperforms rivals like Llama3 and DeepSeek-V3 in multilingual support, visual reasoning, and handling 128k-token contexts. DeepSeek and Kickresume are gaining traction for coding assistance and AI-driven resume optimization. The Sleeper hit is Sunō, an AI music generator creating viral tracks indistinguishable from human-composed hits. ChatGPT tells Man ‘Go to the hospital. NOW!—the doctor said it saved his life. OpenAI's o3 model is raising eyebrows. Users report that it correctly guesses their names and locations from photos, sparking debates about privacy. Some speculate it’s a beta test for advanced contextual awareness. Google’s antitrust breakup echoes the 1984 AT&T split.  Bill Gates predicts AI will end doctor and teacher shortages. ChatGPT users revolt against its ‘toxic positivity’. Subscribers are switching to alternatives like DeepSeek for straightforward answers. Details are scarce, but leaks suggest the Chinese have a device leveraging AI for 10 times faster data processing.  Microsoft Build. AI Tools for developers. From community to hands-on labs, learn your way and skill up for what's next in AI. The world is yours to build. Visit Https://developer.microsoft.com/

Cambridge Mayor Denise Simmons urged the parole board to keep the man who murdered her son behind bars.

Hear from Utah Hockey Club's Rising Star Logan Cooley, who will be eligible for a contract extension this summer. Does he want to stay in Utah? 

On the latest episode of the Kevin O'Connor Show, KOC is joined by Tom Haberstroh to reveal his 2024-25 NBA awards ballot. The pair debate all the biggest honors including Nikola Jokic vs. Shai Gilgeous-Alexander for MVP and Amen Thompson vs. Draymond Green for DPOY. Plus, is Payton Pritchard the undisputed Sixth Man of the Year? And should Cade Cunningham even be ELIGIBLE for Most-Improved Player considering he was a no. 1 overall draft pick??Later, they recap the Minnesota Timberwolves routing of the Memphis Grizzlies. Anthony Edwards dropped 40+ despite Zach Edey finding his footing for Memphis—could the Wolves find themselves the four seed in the West?(0:35) Timberwolves beat Grizzlies Thursday night(3:12) Updated Western Conference playoff picture(11:11) KOC's NBA awards ballots(11:12) SGA vs. Jokic for MVP?(24:54) Stephon Castle for Rookie of the Year?(34:39) Amen Thompson vs. Draymond Green for DPOY?(50:25) Payton Pritchard for 6th Man of the Year?(54:55) Who should win Coach of the Year?(1:00:11) Cade Cunningham MIP controversy